The Drugs Controller General of India has approved the indigenous company Serum Institute of India for the second and third phases of human trials of the corona vaccine.
Let us know that a few days ago, the Serum Institute of India had sought the permission of the Drugs Controller General of India for the second and third phase trials of the Oxford vaccine in the country.
According to the news agency ANI, after an in-depth evaluation, the DCGI has approved the SII to conduct the second and third phase clinical trials of the corona vaccine based on the Subject Expert Committee recommendations.
The official said that the committee recommended approving it, given the data of the trial of Oxford University.
Significantly, the Serum Institute of India has partnered with AstraZeneca to manufacture Oxford's Corona vaccine in the country and has been named Covishield.
At present, the clinical trial of the second and third phases of the Oxford sponsored vaccine is underway in the United Kingdom.
At the same time, the third phase of this vaccine is undergoing trials in Brazil.
Clinical trials for the first and second stages of the vaccine are ongoing in South Africa.
In relation to the partnership with AstraZeneca, SII CEO Adar Poonawalla stated that SII has partnered with AstraZeneca to produce and supply one billion doses of the Covid-19 vaccine being developed by Oxford University.
0 Comments